LONDON, July 31 (Reuters) – AstraZeneca said on
Monday its immunotherapy drug Imfinzi had been granted
“breakthrough” designation by U.S. regulators for treating
non-metastatic lung cancer, following the success of the
so-called Pacific trial.

Read More At Article Source | Article Attribution